2'-Carbohydrate modifications in antisense oligonucleotide therapy: Importance of conformation, configuration and conjugation

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1489, Issue 1, 1999, Pages 117-130

  Manoharan, Muthiah ^a  

^a Isis Pharmaceut 2292 Faraday Ave ^*  (United States)

Author keywords

2' Carbohydrate modification; Antisense oligonucleotide therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARBOHYDRATE; OLIGONUCLEOTIDE; RIBONUCLEASE H;

BINDING AFFINITY; CHEMICAL MODIFICATION; CONFORMATION; CONJUGATION; CROSS LINKING; ENZYME ACTIVATION; PRIORITY JOURNAL; REVIEW;

ALTERNATIVE SPLICING; AMINES; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CARBOHYDRATES; CROSS-LINKING REAGENTS; DRUG DESIGN; ENZYME ACTIVATION; MOLECULAR CONFORMATION; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H, CALF THYMUS; RNA, MESSENGER; SULFHYDRYL COMPOUNDS;

EID: 0032750621     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(99)00138-4     Document Type: Review

References (72)

1. S.T. Crooke, Basic principles of antisense therapeutics, in: S.T. Crooke (Ed.), Antisense Research and Application, vol. 131, Springer, Berlin, 1998, pp. 1-50.
2. S.T. Crooke, Phosphorothioate oligonucleotides, in: S.T. Crooke (Ed.), Therapeutic Applications of Oligonucleotides, R.G. Landes, Austin, 1995, p. 79.
3. R.J. Crouch, M.L. Dirksen, Nucleases, vol. 14, Cold Spring Harbor Monograph Series, Plainview, 1982, pp. 211-254.
4. Crooke S.T., Lemonidis K.M., Neilson L., Griffey R., Lesnik E.A., Monia B.P. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312:1995;599-608.
5. Lima W.F., Mohan V., Crooke S.T. The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J. Biol. Chem. 272:1997;18191-18199.
6. Lima W.F., Crooke S.T. Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. J. Biol. Chem. 272:1997;27513-27516.
7. Lima W.F., Crooke S.T. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry. 36:1997;390-398.
8. Wu H., Lima W.F., Crooke S.T. Molecular cloning and expression of cDNA for human RNase H. Antisense Nucleic Acid Drug Dev. 8:1998;53-61.
9. H. Wu, W.F. Lima, S.T. Crooke, Properties of cloned and expressed human RNase H1, J. Biol. Chem. (1999) in press.
10. Dash P., Lotan I., Knapp M., Kandell E.R., Goelet P. Selective elimination of mRNA in vivo: complementary oligodeoxynucleotides promote RNA depredation by an RNase H-like activity. Proc. Natl. Acad. Sci. USA. 22:1987;7896-7900.
11. Fedoroff O., Salazar M., Reid B.R. Structure of a DNA:RNA hybrid duplex. Why RNase H does not cleave pure RNA. J. Mol. Biol. 233:1993;509-523.
12. Nakamura H., Oda Y., Iwai S., Inoue H., Ohtsuka E., Kanaya S., Kimura S., Katsuda C., Katayanagi K., Morikawa K., et al. How does RNase H recognize a DNA.RNA hybrid? Proc. Natl. Acad. Sci. USA. 88:1991;11535-11539.
13. Inoue H., Hayase Y., Iwai S., Ohtsuka E. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett. 215:1987;327-330.
14. P.D. Cook, Second generation antisense oligonucleotides: 2′-modifications, in: J.A. Bristol (Ed.), Annual Reports in Medicinal Chemistry, vol. 33, Academic Press, San Diego, 1998, pp. 313-325.
15. De Mesmaeker A., Häner R., Martin P., Moser H.E. Antisense oligonucleotides. Acc. Chem. Res. 28:1995;366-374.
16. De Mesmaeker A., Altmann K.-H., Waldner A., Wendeborn S. Backbone modifications in oligonucleotides and peptide nucleic acid systems. Curr. Opin. Struct. Biol. 5:1995;343-355.
17. Egli M. Structural aspects of nucleic acid analogs and antisense oligonucleotides. Angew. Chem. Int. Ed. Engl. 35:1996;1894-1909.
18. Herdewijn P. Targeting RNA with conformationally restricted oligonucleotides. Liebigs Ann. Chem. 00:1996;1337-1348.
19. Egli M. Conformational preorganization, hydration, and nucleic acid duplex stability. Antisense Nucleic Acid Drug Dev. 8:1998;123-128.
20. Cummins L.L., Owens S.R., Risen L.M., Lesnik E.A., Freier S.M., McGee D., Guinosso C.J., Cook P.D. Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res. 23:1995;2019-2024.
21. Lesnik E.A., Guinosso C.J., Kawasaki A.M., Sasmor H., Zounes M., Cummins L.L., Ecker D.J., Cook P.D., Freier S.M. Oligodeoxynucleotides containing 2′-O-modified adenosine: synthesis and effects on stability of DNA:RNA duplexes. Biochemistry. 32:1993;7832-7838.
22. Kawasaki A.M., Casper M.D., Freier S.M., Lesnik E.A., Zounes M.C., Cummins L.L., Gonzalez C., Cook P.D. Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36:1993;831-841.
23. Martin P. New access to 2′-O-alkylated ribonucleosides and properties of 2′-O-alkylated oligoribonucleotides. Helv. Chim. Acta. 78:1995;486-504.
24. Altmann K.H., Fabbro D., Dean N.M., Geiger T., Monia B.P., Muller M., Nicklin P. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem. Soc. Trans. 24:1996;630-637.
25. Altmann K.-H., Dean N.M., Fabbro D., Freier S.M., Geiger T., Häner R., Hüsken D., Martin P., Monia B.P., Müller M., Natt F., Nicklin P., Phillips J., Pieles U., Sasmor H., Moser H.E. Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia. 50:1996;168-176.
26. Griffey R.H., Monia B.P., Cummins L.L., Freier S., Greig M.J., Guinosso C.J., Lesnik E., Manalili S.M., Mohan V., Owens S., Ross B.R., Sasmor H., Wancewicz E., Weiler K., Wheeler P.D., Cook P.D. 2′-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. J. Med. Chem. 39:1996;5100-5109.
27. Freier S.M., Altmann K.H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25:1997;4429-4443.
28. Manoharan M., Tivel K.L., Andrade L.K., Cook P.D. 2′-O- and 3′-O pyrimidine aminotether-containing oligonucleotides: synthesis and conjugation chemistry. Tetrahedron Lett. 36:1995;3647-3650.
29. Manoharan M., Prakash T.P., Barber-Peoc'h I., Bhat B., Vasquez G., Ross B., Cook P.D. N-(2-Cyanoethoxycarbonyloxy)succinimide: a new reagent for protection of amino groups in oligonucleotides. J. Org. Chem. 64:1999;6468-6472.
30. Cook P.D. Medicinal chemistry of antisense oligonucleotides-future opportunities. Anticancer Drug Des. 6:1991;585-607.
31. P.D. Cook, Medicinal chemistry strategies for antisense research, in: S.T. Crooke, B. Lebleu (Eds.), Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 149-187.
32. Monia B.P., Lesnik E.A., Gonzalez C., Lima W.F., McGee D., Guinosso C.J., Kawasaki A.M., Cook P.D., Freier S.M. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:1993;14514-14522.
33. Baker B.F., Lot S.S., Condon T.P., Cheng-Flournoy S., Lesnik E.A., Sasmor H.M., Bennett C.F. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272:1997;11994-12000.
34. Hanecak R., Brown-Driver V., Fox M.C., Azad R.F., Furusako S., Nozaki C., Ford C., Sasmor H., Anderson K.P. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol. 70:1996;5203-5212.
35. Dunckley M.G., Manoharan M., Villiet P., Eperon I.C., Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet. 7:1998;1083-1090.
36. Dominski Z., Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 90:1993;8673-8677.
37. Takeshima Y., Nishio H., Sakamoto H., Nakamura H., Matsuo M. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J. Clin. Invest. 95:1995;515-520.
38. Sierakowska H., Sambade M.J., Agrawal S., Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 93:1996;12840-12844.
39. Teplova M., Minasov G., Tereshko V., Inamati G.B., Cook P.D., Manoharan M., Egli M. Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 6:1999;535-539.
40. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14:1996;376-387.
41. O. Khatsenko, R. Morgan, R. Geary, in: American Association of Pharmaceutical Scientists Meeting, 1998.
42. Gao W.Y., Storm C., Egan W., Cheng Y.C. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol. Pharmacol. 43:1993;45-50.
43. Wallace T.L., Bazemore S.A., Kornbrust D.J., Cossum P.A. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278:1996;1306-1312.
44. Agrawal S., Zhao Q., Jiang Z., Oliver C., Giles H., Heath J., Serota D. Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev. 7:1997;575-584.
45. Henry S.P., Zuckerman J.E., Rojko J., Hall W.C., Harman R.J., Kitchen D., Crooke S.T. Toxicological properties of several novel oligonucleotide analogs in mice. Anticancer Drug Des. 12:1997;1-14.
46. Henry S.P., Monteith D., Bennett F., Levin A.A. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des. 12:1997;409-420.
47. A.A. Levin, D.K. Monteith, J.M. Leeds, P.L. Nicklin, R.S. Geary, M. Butler, M.V. Templin, S.P. Henry, Toxicity of oligodeoxynucleotide therapeutic agents, in: S.T. Crooke (Ed.), Antisense Research and Applications, vol. 131, Springer, Berlin, 1998, pp. 169-215.
48. Tereshko V., Portmann S., Tay E.C., Martin P., Natt F., Altmann K.H., Egli M. Correlating structure and stability of DNA duplexes with incorporated 2′-O-modified RNA analogues. Biochemistry. 37:1998;10626-10634.
49. Egli M., Portmann S., Usman N. RNA hydration: a detailed look. Biochemistry. 35:1996;8489-8494.
50. Schneider B., Patel K., Berman H.M. Hydration of the phosphate group in double-helical DNA. Biophys. J. 75:1998;2422-2434.
51. Lind K.E., Mohan V., Manoharan M., Ferguson D.M. Structural characteristics of 2′-O-(2-methoxyethyl)-modified nucleic acids from molecular dynamics simulations. Nucleic Acids Res. 26:1998;3694-3699.
52. S.M. Linn, R.J. Roberts, in: Cold Spring Harbor Monograph Series, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1982, p. 378.
53. Manoharan M., Guinosso C.J., Cook P.D. Novel functionalization of the sugar moiety of nucleic acids for multiple labeling in the minor groove. Tetrahedron Lett. 32:1991;7171-7174.
54. Manoharan M., Ramasamy K.S., Mohan V., Cook P.D. Oligonucleotides bearing cationic groups: N2-(3-aminopropyl)deoxyguanosine. Synthesis, enhanced binding properties and conjugation chemistry. Tetrahedron Lett. 37:1996;7675-7678.
55. Kawasaki A.M., Casper M.D., Prakash T.P., Manalili S., Sasmor H.M., Manoharan M., Cook P.D. Synthesis, hybridization, and nuclease resistance properties of 2′-O-aminooxyethyl (2′-O-AOE) modified oligonucleotides. Tetrahedron Lett. 40:1999;661-664.
56. Manoharan M., Tivel K.L., Cook P.D. Lipidic nucleic acids. Tetrahedron Lett. 36:1995;3651-3654.
57. Manoharan M., Tivel K.L., Ross B., Cook P.D. A 2′-O-thiol tether in the ribose moiety of nucleic acids for conjugation chemistry. Gene. 149:1994;147-156.
58. Manoharan M., Johnson L.K., Tivel K.L., Springer R.H., Cook P.D. Introduction of a lipophilic thioether tether in the minor groove of nucleic acids for antisense applications. Bioorg. Med. Chem. Lett. 3:1993;2765-2770.
59. Whittemore N.A., Mullenix A.N., Inamati G.B., Manoharan M., Cook P.D., Tuinman A.A., Baker D.C., Chambers J.Q. Synthesis and electrochemistry of anthraquinone-oligodeoxynucleotide conjugates. Bioconjug. Chem. 10:1999;261-270.
60. Manoharan M., Inamati G., Tivel K.L., Conklin B., Ross B.S., Cook P.D. 2′- and 3′-cholesterol-conjugated adenosine and cytosine nucleoside building blocks: synthesis of lipidic nucleic acids. Nucleosides Nucleotides. 16:1997;1141-1143.
61. Manoharan M., Tivel K.L., Inamati G., Monia B.P., Dean N., Cook P.D. Cholesterol conjugated uniform and gapmer phosphorothioate oligonucleotides targeted against PKC-a and C-raf gene expression. Nucleosides Nucleotides. 16:1997;1139-1140.
62. Manoharan M., Tivel K.L., Condon T.P., Andrade L.K., Barber-Peoch I., Inamati G., Shah S., Mohan V., Graham M.J., Bennett C.F., Crooke S.T., Cook P.D. Conjugated antisense oligonucleotides. Nucleosides Nucleotides. 16:1997;1129-1138.
63. Manoharan M., Tivel K.L., Zhao M., Nafisi K., Netzel T.L. Base-sequence dependence of emission lifetimes for D141018-30-6NA oligomers and duplexes covalently labeled with pyrene: relative electron-transfer quenching efficiencies of A, G, C, and T nucleotides toward pyrene. J. Phys. Chem. 99:1995;17461-17472.
64. Crooke S.T., Graham M.J., Zuckerman J.E., Brooks D., Conklin B.S., Cummins L.L., Greig M.J., Guinosso C.J., Kornbrust D., Manoharan M., Sasmor H.M., Schleich T., Tivel K.L., Griffey R.H. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277:1996;923-937.
65. Manoharan M., Andrade L.K., Cook P.D. Site-specific cross-linking of nucleic acids using the abasic site. Org. Lett. 1:1999;311-314.
66. Damha M.J., Wilds C.J., Noronha A., Brukner I., Borkow G., Arion D., Parniak M.A. Hybrids of RNA and arabinonucleic acids (ANA and 2′-F-ANA) are substrates of ribonuclease H. J. Am. Chem. Soc. 120:1998;12976-12977.
67. Venkateswarlu D., Ferguson D.M. Effects of C2′-substitution on arabinonucleic acid structure and conformation. J. Am. Chem. Soc. 121:1999;5609-5610.
68. Venkateswarlu D., Lind K.E., Mohan V., Manoharan M., Ferguson D.M. Structural properties of DNA:RNA duplexes containing 2′-O-methyl and 2′-S-methyl substitutions: a molecular dynamics investigation. Nucleic Acids Res. 27:1999;2189-2195.
69. Fraser A., Wheeler P., Cook P.D., Sanghvi Y.S. Synthesis and conformational properties of 2′-deoxy-2′-methylthio-pyrimidine and -purine nucleosides: potential antisense applications. J. Heter. Chem. 30:1993;1277-1287.
70. R.H. Griffey, E. Lesnik, S. Freier, Y.S. Sanghvi, K. Teng, A. Kawasaki, C. Guinosso, P. Wheeler, V. Mohan, P.D. Cook, New twists on nucleic acids: structural properties of modified nucleosides incorporated into oligonucleotides, in: Y.S. Sanghvi, P.D. Cook (Eds.), Carbohydrate Modifications in Antisense Research, American Chemical Society, Washington, DC, 1994, pp. 212-224.
71. Ross B.S., Springer R.H., Tortorici Z., Dimock S. A novel and economical synthesis of 2′-O-alkyl-uridines. Nucleosides Nucleotides. 16:1997;1641-1643.
72. M. Manoharan, Designer antisense oligonucleotides: conjugation chemistry and functionality placement, in: S.T. Crooke, B. Lebleu (Eds.), Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 303-349.